JP2021518162A5 - - Google Patents

Info

Publication number
JP2021518162A5
JP2021518162A5 JP2020573082A JP2020573082A JP2021518162A5 JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5 JP 2020573082 A JP2020573082 A JP 2020573082A JP 2020573082 A JP2020573082 A JP 2020573082A JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5
Authority
JP
Japan
Prior art keywords
item
modified
immunoeffector
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022366 external-priority patent/WO2019178422A1/en
Publication of JP2021518162A publication Critical patent/JP2021518162A/ja
Publication of JP2021518162A5 publication Critical patent/JP2021518162A5/ja
Priority to JP2024070727A priority Critical patent/JP2024091902A/ja
Pending legal-status Critical Current

Links

JP2020573082A 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 Pending JP2021518162A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070727A JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201862643578P 2018-03-15 2018-03-15
US201862643582P 2018-03-15 2018-03-15
US62/643,582 2018-03-15
US62/643,578 2018-03-15
US201862692010P 2018-06-29 2018-06-29
US201862692014P 2018-06-29 2018-06-29
US62/692,014 2018-06-29
US62/692,010 2018-06-29
US201862714337P 2018-08-03 2018-08-03
US201862714333P 2018-08-03 2018-08-03
US62/714,337 2018-08-03
US62/714,333 2018-08-03
US201862768462P 2018-11-16 2018-11-16
US201862768459P 2018-11-16 2018-11-16
US201862768428P 2018-11-16 2018-11-16
US201862768430P 2018-11-16 2018-11-16
US62/768,462 2018-11-16
US62/768,428 2018-11-16
US62/768,430 2018-11-16
US62/768,459 2018-11-16
US201962804259P 2019-02-12 2019-02-12
US62/804,259 2019-02-12
PCT/US2019/022366 WO2019178422A1 (en) 2018-03-15 2019-03-14 Gene-regulating compositions and methods for improved immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070727A Division JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Publications (2)

Publication Number Publication Date
JP2021518162A JP2021518162A (ja) 2021-08-02
JP2021518162A5 true JP2021518162A5 (enExample) 2022-03-18

Family

ID=67903888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573082A Pending JP2021518162A (ja) 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Country Status (9)

Country Link
US (2) US20190284529A1 (enExample)
EP (1) EP3765608A4 (enExample)
JP (2) JP2021518162A (enExample)
KR (2) KR20250174987A (enExample)
CN (1) CN112041433A (enExample)
AU (2) AU2019236205A1 (enExample)
BR (1) BR112020018573A2 (enExample)
CA (1) CA3093968A1 (enExample)
WO (1) WO2019178422A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178420A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
EP3917541A4 (en) * 2019-01-28 2022-12-07 Bar Ilan University Combinations, nanoparticles and methods for controlling natural killer cell activation and function
CA3128823A1 (en) * 2019-02-04 2020-08-13 KSQ Therapeutics, Inc. Combination gene targets for improved immunotherapy
EP3930731A4 (en) 2019-02-26 2022-11-23 Rambam Med-Tech Ltd. CELLS AND METHODS FOR IMPROVED IMMUNOTHERAPY
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
CA3162896A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Engineered t cells and tumor-infiltrating lymphocytes to overcome immunosuppression in the tumor microenvironment
CN114929853A (zh) * 2019-11-27 2022-08-19 得克萨斯大学体系董事会 用于治疗胶质母细胞瘤和其他癌症的天然杀伤细胞免疫疗法
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
WO2021119555A2 (en) * 2019-12-12 2021-06-17 Kumquat Biosciences Inc. Compositions and methods for potentiating immune response
EP4073242A4 (en) * 2019-12-12 2024-01-03 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
EP3845646A1 (en) * 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
CN113151178B (zh) * 2020-01-07 2022-09-09 清华大学 敲除Rc3h1基因和/或Zc3h12a基因的重组T细胞及其应用
CN116948964A (zh) 2020-11-19 2023-10-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
US20230364138A1 (en) * 2020-11-23 2023-11-16 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
AU2021392809A1 (en) * 2020-12-03 2023-07-20 Nkarta, Inc. Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
WO2022186297A1 (ja) * 2021-03-02 2022-09-09 花王株式会社 アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
JP2024518421A (ja) * 2021-05-07 2024-05-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キメラ抗原受容体（ｃａｒ）ｔ細胞治療に関連する血清メタボロミクス
CN113234834A (zh) * 2021-07-09 2021-08-10 北京泱深生物信息技术有限公司 一组用于胰腺癌预后的基因及其应用
WO2023015213A1 (en) * 2021-08-03 2023-02-09 Spotlight Therapeutics Ptpn2 specific guide rnas and uses thereof
US20240360410A1 (en) * 2021-08-03 2024-10-31 Suzhou Grit Biotechnology Co., Ltd. Modified tumor infiltrating lymphocyte and use thereof
CN113430202A (zh) * 2021-08-26 2021-09-24 山东兴瑞生物科技有限公司 一种具有高敲除率的人PD1基因sgRNA及含有该sgRNA的质粒、T细胞
US20240390493A1 (en) * 2021-09-29 2024-11-28 The Johns Hopkins University Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
GB202114871D0 (en) * 2021-10-18 2021-12-01 Ucl Business Ltd Guide RNA and uses thereof
CN114134177B (zh) * 2021-11-19 2022-11-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 敲除Setd5的小鼠模型和抵御急性T淋巴细胞白血病小鼠模型的构建方法和应用
EP4471128A4 (en) * 2022-01-29 2026-03-04 Suzhou Grit Biotechnology Co Ltd Modified tumor infiltrating lymphocyte and use thereof
WO2023184107A1 (en) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating mecp2-associated diseases
EP4260932A1 (en) 2022-04-13 2023-10-18 GEA Process Engineering A/S Method and system for reducing water consumption in a membrane dealcoholization process
EP4276174A1 (en) * 2022-05-09 2023-11-15 Cellectis S.A. Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
CN119630792A (zh) * 2022-08-24 2025-03-14 莱兰斯坦福初级大学评议会 用于原代免疫细胞工程化改造的多重化rna调节平台
TW202417626A (zh) * 2022-09-13 2024-05-01 美商亞森諾生物科學公司 具有共表現的ｔｇｆｂｒ ｓｈｒｎａ之免疫細胞
EP4382118B1 (en) * 2022-12-07 2025-08-20 Eberhard Karls Universität Tübingen, Medizinische Fakultät Modified immune cell
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
EP4720059A1 (en) 2023-05-24 2026-04-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR102637929B1 (ko) * 2023-08-07 2024-02-20 충남대학교 산학협력단 면역관문 억제제의 효능 예측용 pbrm1 유전자 마커및 이의 용도
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304124A1 (en) * 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
US20160017286A1 (en) * 2013-03-06 2016-01-21 The Trustees Of The University Of Pennsylvania Ikaros inhibition to augment adoptive t cell transfer
RU2725542C2 (ru) * 2013-05-13 2020-07-02 Селлектис Способы конструирования высокоактивных т-клеток для иммунотерапии
US20170224731A1 (en) * 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20170049709A1 (en) * 2015-08-21 2017-02-23 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Similar Documents

Publication Publication Date Title
JP2021518161A5 (enExample)
JP2021518160A5 (enExample)
JP7551815B2 (ja) Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製
JP2022519595A5 (enExample)
CN110168078B (zh) 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
KR102495308B1 (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
CN116322716A (zh) Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
KR20210008502A (ko) 암을 치료하기 위한 방법 및 조성물
JP2022519595A (ja) 免疫療法の改善のための遺伝子標的の組み合わせ
US20200017881A1 (en) Programmable Oncolytic Virus Vaccine System and Method
WO2020160217A1 (en) Microenvironment sensors to regulate engineered gene expression
JP2025156332A (ja) エクスビボ細胞療法用途のための免疫細胞の操作
JP2022519070A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
WO2023123195A1 (zh) 一种目的基因可调控的工程化免疫细胞及其制备方法和应用
US20240150711A1 (en) Personalized redirection and reprogramming of t cells for precise targeting of tumors
US20260108604A1 (en) Car t cell compositions for treatment of cancer
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
CA3256913A1 (en) NUCLEIC ACID MODIFIED BIOLOGICAL CELL WITH EXPANSION-DEPENDENT GENE EXPRESSION
JP2010521460A (ja) 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
Navarre et al. Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses
WO2020190936A1 (en) Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor
Babu et al. Cancer gene therapies progress in pre and postgenomics era
WO2025146440A1 (en) Use of lmo4 to bolster stemness and antitumor efficacy of t-cells
Hagner et al. 646. Covalently-Closed, Dumbbell-Shaped Double-Stem-Loop DNA Constructs (dSLIM) with Specific Immunomodulatory Function
Yoon et al. 116. Overcoming CAR-Dependency of Oncolytic Adenovirus via Adenoviral Fiber Modification with Vesicular Stomatitis Virus Glycoprotein Epitope for Enhanced Antitumor Efficacy